Table 1. Patient characteristics and in vitro treatments.

Pt, patients; No, number; MSC, mesenchymal stromal cell; siRNA, small interfering RNA; CECA, cyclophosphamide, etoposide, carboplatin, and cytosine arabinoside; P/Q, apoptosis in proliferating and quiescent cells; WB, Western blot; % Q cells, percentage of quiescent cells over total CD34+ cells; KD, knockdown.

Pt.
no.
SourceBlast
(%)
BCR-ABL
status
Treatments and
responses
In vitro treatment
and assays
% Q
cells
Days of
coculture
with MSC
Cells in which
apoptosis was
determined
WB/
PCR
Bcl-XL/
Mcl-1 KD
1PB91T315I, E255KResistant to imatinib; treated with
chemotherapy and dasatinib
P/QBulk/CD34+38/
CD34+38+
9.46
2PB89T315I, E255VResistant to imatinib, dasatinib,
nilotinib, and ponatinib
P/QBulk/CD34+38
CD34+38+
Protein/
RNA
siRNAs15.97
3PB83H396RFailed imatinib, dasatinib,
and nilotinib
P/QBulk/CD34+38
CD34+38+
siRNAs22.110
4aPB89T315I, E255BResistant to imatinib, nilotinib,
dasatinib, and ponatinib; treated
with CECA, ponatinib, and dasatinib
Bulk/CD34+38
CD34+38+
Protein/
RNA
siRNAs
5PB80No mutationResistant to imatinib and dasatinibBulkProtein/
RNA
6BM93No mutationFailed imatinib; treated with nilotinibBulk/CD34+38
CD34+38+
4bPB62T315I, E255VResistant to imatinib, dasatinib,
and ponatinib; treated with
nilotinib, decitabine, and dasatinib
P/Q7.76
7PB24No mutationResistant to imatinib; treated
with nilotinib
P/Q6.88
8PB11No mutationResistant to imatinib, dasatinib,
nilotinib, and ponatinib; treated
with decitabine, dasatinib, and
bosutinib
P/Q14.47